Wet AMD patients in the PRISM Phase 2b trial received a single intravitreal injection of 4D-150 two years ago, and the durability question that hangs over every gene therapy program just got a meaningful answer. 4D Molecular Therapeutics reported positive 2-year data from the trial on July 18, 2026, a readout that matters less as a standalone result and more as the foundation underneath two ongoing Phase 3 trials. The asymmetry worth noting: the entire rationale for a one-and-done gene therapy rests on sustained efficacy at year two and beyond, because a therapy that fades by month 18 is simply a very expensive injection with extra steps.
The trial enrolled 45 patients across two dose levels of a single intravitreal dose. Thirty patients received the 3E10 vg/eye dose selected for the Phase 3 program, and 15 received the lower 1E10 vg/eye dose. That split matters for interpreting the data: the Phase 3-relevant cohort is the 30-patient group, and any signal degradation at the lower dose is a separate story from what investors and regulators will anchor on. 4D-150 uses 4DMT’s engineered R100 AAV vector for intravitreal delivery and expresses both aflibercept and a microRNA targeting VEGF-C, a dual-transgene architecture designed precisely to sustain suppression of angiogenic signaling long enough to make repeat dosing unnecessary. Two years is the first real test of whether that design assumption holds in a broad wet AMD population, not a cherry-picked subgroup.
The competitive context is genuine pressure, not background noise. Wet AMD already has multiple approved anti-VEGF agents including aflibercept, bevacizumab, and ranibizumab, all requiring recurring injections that create the treatment burden gene therapy aims to eliminate. The clinical argument for 4D-150 has always been treatment-burden reduction rather than superior visual acuity gains, which means the durability data at year two is the core commercial claim, not a secondary endpoint. If suppression of neovascular activity holds without rescue injections through 24 months in the majority of the 3E10 cohort, the Phase 3 program has a credible efficacy bridge. If rescue injection rates crept up in year two, that story becomes considerably harder to tell to retinal specialists who already have workable alternatives.
The single number to track from here is the proportion of patients in the 3E10 cohort who remained injection-free through the full 24-month observation window. That figure will either validate the gene therapy durability premise heading into Phase 3 or force a reassessment of what the program can actually promise.
Source link: https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
